LOGIN  |  REGISTER

Latest Medical Stock News

FILTER BY TOPIC:     Medical Devices   Diagnostics & Research   FDA 510(k) Clearance   Psychedelics        List of All Medical Stocks  

Lifeward Announces the Appointment of Mike Swinford to its Board of Directors

April 19
Last Trade: 4.78 0.00 0.00

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market lead delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, announced that the Board has approved the appointment...Read more


Intuitive Surgical Announces First Quarter Earnings

April 18
Last Trade: 366.34 -6.29 -1.69

SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023. The Company placed 313 da Vinci surgical systems,...Read more


Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention  

April 18
Last Trade: 23.84 -0.17 -0.71

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a...Read more


NeoGenomics Announces Senior Leadership Promotions

April 18
Last Trade: 13.53 -0.24 -1.74

FT. MYERS, Fla. / Apr 18, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted to Chief Commercial Officer and will lead NeoGenomics’ clinical and pharma services commercial teams. Stone will be responsible for sales, marketing, pharma project management, commercial...Read more


AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

April 18
Last Trade: 23.20 -0.19 -0.81

MASON, Ohio / Apr 18, 2024 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is...Read more


NEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024

April 18
Last Trade: 2.17 -0.04 -1.81

LANGHORNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: VEGAS 2024, taking place at the Paris Hotel and Casino, Las...Read more


Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics

April 18
Last Trade: 1.35 -0.13 -8.78

REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline...Read more


Genetic Technologies Announces $2 Million Registered Direct Offering

April 18
Last Trade: 2.32 -0.12 -4.92

MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS...Read more


Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

April 18
Last Trade: 2.74 -0.06 -2.14

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal third quarter and nine months ended March 31, 2024. The Company expects approximate unaudited revenue of $0.82 million for the three months ended March 31,...Read more


Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges

April 17
Last Trade: 107.30 2.03 1.93

Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT)...Read more


AdaptHealth Appoints Suzanne Foster as Chief Executive Officer

April 17
Last Trade: 9.34 -0.02 -0.21

PLYMOUTH MEETING, Pa. / Apr 17, 2024 / Business Wire / AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer. Ms. Foster will assume leadership of the Company from interim CEO and...Read more


Treace Medical Concepts to Present at Bank of America Health Care Conference

April 17
Last Trade: 10.97 -0.30 -2.66

PONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate...Read more


Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.

April 17
Last Trade: 2.32 0.07 3.11

Agreement designed to provide patients and caregivers access to innovative home dialysis with the Tablo® Hemodialysis System SAN JOSE, Calif. / Apr 17, 2024 / Business Wire / Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced...Read more


Allurion Technologies Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments

April 17
Last Trade: 1.99 -0.05 -2.45

Simplifies capital structure through prepayment of existing term loan Reduces annual interest expense, providing increased near-term cash flow and operational flexibility Extends expected cash runway in advance of AUDACITY FDA trial read-out Strengthens long-term partnership with RTW Investments NATICK, Mass. / Apr 17, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated...Read more


Hyperfine: Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study

April 17
Last Trade: 0.83 0.02 2.47

Study will assess the clinical utility and workflow benefits of physicians using images acquired by the Swoop® Portable MR Imaging® system to identify ARIA events in Alzheimer’s patients treated with amyloid-targeting therapy GUILFORD, Conn. / Apr 17, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance...Read more


Bionano Genomics and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

April 17
Last Trade: 0.75 -0.04 -4.73

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome karyotype...Read more


CytoSorbents: STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

April 17
Last Trade: 0.80 0.001 0.12

PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be...Read more


New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

April 16
Last Trade: 18.50 -0.01 -0.05

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other...Read more


Orthofix Medical Names Andres Cedron as New Chief Legal Officer

April 16
Last Trade: 13.10 0.08 0.61

LEWISVILLE, Texas / Apr 16, 2024 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer. Cedron most recently served as Vice President and Corporate Secretary at Stryker Corporation, a $20B+ global medical device company. In his corporate officer position, Cedron oversaw Stryker’s corporate governance, SEC...Read more


CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

April 16
Last Trade: 8.31 0.24 2.97

BRISBANE, Calif. / Apr 16, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15,...Read more


PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

April 16
Last Trade: 1.55 0.09 6.16

Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif., April 16, 2024  /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million in...Read more


New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

April 16
Last Trade: 4.62 -0.16 -3.35

IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 Charing Cross International Symposium being held April 23rd - 25th in London, England. The presentation, entitled "Efficacy...Read more


Perimeter Medical Imaging AI Announces Webinar Featuring AI Expert, Anantha Kancherla, Discussing Trends in the Use of Machine Learning and Artificial Intelligence in Healthcare Applications

April 16
Last Trade: 0.77 0.00 0.00

TORONTO and DALLAS, April 16, 2024 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced a newly published webinar, "Trends in Artificial Intelligence (AI) and Innovators in Healthcare" featuring a fireside chat with Anantha Kancherla, former head of Meta's AI platform, and current member of Perimeter's...Read more


Inspira Technologies Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures

April 16
Last Trade: 1.80 -0.0099 -0.55

RA'ANANA, Israel, April 16, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is proud to announce the signing of a collaboration term sheet (the "Term Sheet") with the Beilinson Hospital in Israel for the evaluation of its proprietary INSPIRA ART100 device (the "Device") in organ transplant procedures. This Term Sheet...Read more


INVO Bioscience Reports Fourth Quarter and Full Year 2023 Financial Results

April 16
Last Trade: 1.37 -0.15 -9.87

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal...Read more


Agilent Technologies Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay

April 15
Last Trade: 132.73 0.29 0.22

SANTA CLARA, Calif. / Apr 15, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU. In...Read more


Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

April 15
Last Trade: 201.48 2.03 1.02

Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based...Read more


Revvity Signals Software’s New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners

April 15
Last Trade: 100.86 1.48 1.49

New CRO system-level expansion elevates data stewardship and enables organizations to gain more insight with less oversight WALTHAM, Mass. / Apr 15, 2024 / Business Wire / Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, will launch Signals SynergyTM, a software solution designed to drive greater collaboration, project management, and data exchange between pharmaceutical and...Read more


Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

April 15
Last Trade: 60.96 -2.52 -3.97

MADISON, Wis. / Apr 15, 2024 / Business Wire / Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve...Read more


Envista Announces CEO Appointment

April 15
Last Trade: 19.96 0.21 1.06

BREA, Calif., April 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) announced today the appointment of Paul Keel as Chief Executive Officer and a member of the Board of Directors effective May 1, 2024. He succeeds Amir Aghdaei, who will continue to support the transition as a senior advisor. "Paul's strong track record as CEO of a public, diversified, global innovation company makes him the right leader for Envista at...Read more


CVRx announces availability of additional data supporting long-term benefits of Barostim

April 15
Last Trade: 14.90 -0.36 -2.36

BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These...Read more


TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

April 15
Last Trade: 4.75 -0.40 -7.77

MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and robotic-assisted inguinal hernia repair. OviTex IHR is available in three configurations,...Read more


IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

April 15
Last Trade: 1.21 -0.02 -1.63

Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons  President-Elect of the ASBrS, Dr. Michael Berry, presents data and states "cryoablation is ready for prime time"  Company seeks indication for treating women with early stage T1 invasive breast cancer with adjuvant hormone therapy  Available...Read more


Biomerica provides update on inFoods® IBS expansion

April 15
Last Trade: 0.73 -0.03 -3.91

Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. Average quarterly increase in physicians prescribing inFoods more than doubled each quarter over the past 12 months. Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. Company receives notice of allowance for five new patents in Europe,...Read more


Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

April 15
Last Trade: 1.10 -0.05 -4.35

SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment...Read more


Co-Diagnostics Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event

April 12
Last Trade: 1.15 -0.01 -0.86

Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries SALT LAKE CITY, April 12, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it held the ribbon cutting event for its new manufacturing facility yesterday in the City...Read more


Numinus Wellness Announces Second Quarter Fiscal 2024 Results

April 12
Last Trade: 0.09 -0.005 -5.56

Q2 Fiscal 2024 Highlights Cash position of $6.6 million as of February 29, 2024 Gross profit of $0.5 million, a 22.7% decline over Q1 2024 Revenue of $5.0 million, a 15.4% decline over Q1 2024 Enrolment in Numinus training programs doubled to over 1,400 learners, compared to over 700 in Q1 2024 Managed 15 clinical trials at Cedar Clinical Research Provided 17,661 client appointments in Numinus Wellness Clinics Subsequent to...Read more


Biomerica Reports Third Quarter 2024 Financial Results

April 12
Last Trade: 0.73 -0.03 -3.91

Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024  InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syndrome (IBS) Clinical Session Company in discussions with Key Clinical Lab Customers for Use of its Recently US FDA 510(k) Cleared Hp Detect™...Read more


Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

April 11
Last Trade: 39.47 -0.18 -0.45

Five new launches reinforce Baxter’s focus on differentiated products and enhance the company’s Pharmaceuticals portfolio in critical therapeutic areas Products feature ready-to-use formulations to help support patient safety and offer added convenience for healthcare professionals DEERFIELD, Ill. / Apr 11, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding,...Read more


Charles River Laboratories and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

April 11
Last Trade: 226.78 -0.77 -0.34

Powered by digital pathology and AI algorithms, Patholytix Foresight drives speed and quality in toxicologic pathology practices WILMINGTON, Mass. & DUBLIN / Apr 11, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology...Read more


Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

April 11
Last Trade: 85.28 -2.00 -2.29

ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy AUSTIN, Texas / Apr 11, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The...Read more


Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

April 11
Last Trade: 10.75 0.35 3.37

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical...Read more


Monogram Orthopaedics Accepted to NVIDIA Inception Program

April 11
Last Trade: 2.25 -0.01 -0.44

Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs System AUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through...Read more


Bionano Genomics Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

April 11
Last Trade: 0.75 -0.04 -4.73

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically relevant genomic variations in pediatric B-cell acute lymphoblastic leukemia (B-ALL). The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches...Read more


Apyx Medical Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit

April 11
Last Trade: 1.32 -0.06 -4.35

Shaping the Future of Aesthetic Treatments with Advanced Medical Technology CLEARWATER, Fla. / Apr 11, 2024 / Business Wire / Apyx® Medical Corporation (NASDAQ:APYX) (the “Apyx Medical”; “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024. The Renuvion Users’ Summit...Read more


Cutera Announces the North America Launch of xeo®+

April 11
Last Trade: 1.95 -0.35 -15.22

A legacy in the aesthetics industry, xeo+ offers new and innovative features BRISBANE, Calif. / Apr 11, 2024 / Business Wire / Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announces the launch of xeo+, a pioneering laser and light-based multi-application platform built on a rich history of excellence in performance and innovation. The xeo+ offers providers updated features and newly...Read more


Ventripoint Diagnostics Announces Non-Brokered Convertible Debenture Private Placement

April 11
Last Trade: 0.22 0.005 2.38

Toronto, Ontario – TheNewswire - April 11, 2024 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces that it intends to complete, subject to TSXV Venture Exchange (the “Exchange”) acceptance, a non-brokered private placement of up to CDN$3,000,000 (the “Offering”) of unsecured convertible debentures (“Debentures”). Depending on market conditions, the Corporation may increase the size of the Offering,...Read more


Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader

April 11
Last Trade: 2.74 -0.06 -2.14

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening of the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, with the grant of a new European patent with unitary effect for its ground-breaking DSR-Plus...Read more


Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

April 10
Last Trade: 79.48 0.29 0.37

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy DUBLIN, April 10, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along...Read more


Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit

April 10
Last Trade: 201.48 2.03 1.02

The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment BURLINGTON, N.C., April 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox  PCR Test Home...Read more


Henry Schein Announces Appointment of Three New Members to the Company’s Executive Management Committee

April 10
Last Trade: 70.86 0.89 1.27

Joining Henry Schein’s EMC are Steve Boggan and Bianka Wilson, Co-CEOs of the Global Oral Reconstruction Group, and Tom Popeck, CEO of the Healthcare Specialties Group MELVILLE, N.Y. / Apr 10, 2024 / Business Wire / Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today announced that it has appointed three new members to the Company’s Executive...Read more


QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay

April 10
Last Trade: 39.12 0.86 2.25

Helping hospital and emergency room customers respond to the critical demand for enhanced opioid testing SAN DIEGO / Apr 10, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay (“MPA”). This Fentanyl assay will help hospital and emergency room...Read more


Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications...

April 10
Last Trade: 5.13 -0.11 -2.10

MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the results as published in the American Journal of Ophthalmology (“AJO”) International of the large scale, comparative real-world...Read more


Spectral Medical Provides Tigris Trial Update

April 10
Last Trade: 0.44 0.00 0.00

101 patients enrolled TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic...Read more


Neuronetics: New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

April 10
Last Trade: 3.80 -0.03 -0.78

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in the...Read more


DarioHealth Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

April 10
Last Trade: 1.16 0.01 0.87

Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens NEW YORK, April 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized...Read more


Inspira Technologies and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

April 10
Last Trade: 1.80 -0.0099 -0.55

RA'ANANA, Israel, April 10, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, together with Ennocure MedTech Ltd. ("Ennocure"), announced results from their collaborative development of a proprietary bio-electronic treatment to prevent associated bloodstream infections in patients in intensive care units. Once developed,...Read more


Sanuwave Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024)

April 10
Last Trade: 0.02 -0.0001 -0.42

SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history. Q1 2024 revenue increased between 51% and 56% compared to Q1 2023. UltraMist revenues for Q1 2024 increased by more than 55% versus Q1 2023 and accounted for approximately 95% of the Company’s total revenues. UltraMist applicator sales were an all...Read more


Telo Genomics Receives Accreditation from College of American Pathologists

April 10
Last Trade: 0.17 -0.04 -17.07

Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to TELO's...Read more


Hamilton Thorne to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 10
Last Trade: 1.35 0.00 0.00

Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets., will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16...Read more


Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

April 9
Last Trade: 117.43 0.74 0.63

Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team...Read more


Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

April 9
Last Trade: 296.10 1.87 0.64

News Summary: New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi. Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted analyte interactions to increase resolution and sensitivity while reducing peak tailing for metal-sensitive analytes. Next-generation system delivers a...Read more


Charles River Laboratories Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

April 9
Last Trade: 226.78 -0.77 -0.34

HQ plasmid DNA production to support Phase I trials for gene therapy targeting Bardet-Biedl Syndrome WILMINGTON, Mass. / Apr 09, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the...Read more


Neogen Announces Third-Quarter 2024 Results

April 9
Last Trade: 11.61 -0.32 -2.68

Revenue of $228.8 million. Net loss of $(2.0) million; $(0.01) per diluted share. Adjusted Net Income of $26.4 million; $0.12 per diluted share. Adjusted EBITDA of $52.7 million. Updating full-year outlook. LANSING, Mich., April 9, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter ended February 29, 2024. "The third quarter saw us complete a number of milestone achievements...Read more


Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

April 9
Last Trade: 17.28 -0.39 -2.21

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development...Read more


Nano-X Imaging Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

April 9
Last Trade: 8.60 -0.47 -5.18

AhealthZ to aid Nanox’s pursuit of local authorizations and licenses for Nanox.ARC in South Korea SCL Science to integrate Nanox’s artificial intelligence solutions in operations PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox...Read more


CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Late-Breaking Abstract Presentation to Showcase Results from SHORE Registry Highlighting Benefits of Surveillance with HeartCare BRISBANE, Calif. / Apr 09, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –...Read more


Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

Studies highlight advancements in technology to detect cell-free DNA and rapid turnaround time in a real-world clinical setting LOUISVILLE, Colo. / Apr 09, 2024 / Business Wire / Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. These...Read more


enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

April 9
Last Trade: 4.62 -0.16 -3.35

Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve® PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024 IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...Read more


HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables SANTA CLARA, Calif. / Apr 09, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company...Read more


Mainz Biomed Reports Full Year 2023 Financial Results

April 9
Last Trade: 0.91 0.001 0.11

BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023. “This past fiscal year represented an important period of progress for the Company highlighted by reporting results from our groundbreaking...Read more


Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

April 9
Last Trade: 1.43 -0.04 -2.72

The new Gen-3 HALO™ Clarity 15 milliamp (mA) HOUSTON, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced it has completed the first full production test run and successfully performed usability, feasibility design verification, and electrical safety testing for its new Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device in the U.S. As a result,...Read more


Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

April 9
Last Trade: 0.26 -0.0034 -1.31

MINNEAPOLIS, April 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that Detroit, Michigan-based health system, Henry Ford Health, has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company’s Aquadex SmartFlow system as part of Nuwellis’ pivotal REVERSE-HF clinical study. “We are excited to study the impact of Aquadex SmartFlow therapy on our heart...Read more


The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

April 8
Last Trade: 79.48 0.29 0.37

EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April 8, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation...Read more


Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module

April 8
Last Trade: 67.33 -0.09 -0.13

MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the...Read more


IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud

April 8
Last Trade: 228.09 0.92 0.40

RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO, CA / Apr 08, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life...Read more


Shockwave Medical Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

April 8
Last Trade: 329.00 1.48 0.45

SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three years. These findings confirm the positive,...Read more


Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

April 8
Last Trade: 60.96 -2.52 -3.97

First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test1 MADISON, Wis. / Apr 08, 2024 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the...Read more


Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

April 8
Last Trade: 77.76 -0.80 -1.02

ASILOMAR, Calif. / Apr 08, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates. At the 65th ENC (www.enc-conference.org), Bruker introduces...Read more


Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

April 8
Last Trade: 77.76 -0.80 -1.02

ASILOMAR, Calif. / Apr 08, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT). At the 65th ENC (www.enc-conference.org), Bruker...Read more


Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

April 8
Last Trade: 85.28 -2.00 -2.29

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics AUSTIN, Texas / Apr 08, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived...Read more


Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

April 8
Last Trade: 2.52 -0.02 -0.79

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibility to the Imaging Mass Cytometry™ workflow on the Hyperion XTi™ Imaging System. Spatial biology is vital to clinical and translational research, providing critical...Read more


TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

April 8
Last Trade: 4.75 -0.40 -7.77

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his...Read more


electroCore Announces the Launch of Truvaga Plus® for General Wellness

April 8
Last Trade: 5.65 0.01 0.18

ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Our first general wellness product, Truvaga 350, exceeded our expectations and Truvaga Plus will be an...Read more


Petvivo To Exhibit At The IVAPM Pain Management Forum In Indianapolis, Indiana

April 8
Last Trade: 0.74 0.02 2.08

MINNEAPOLIS, April 08, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it is a Silver Sponsor and will be exhibiting at the International Veterinary Academy of Pain Management (“IVAPM”) Pain Management Forum to be held April 14nd to April 16th 2024 at the JW Marriott...Read more


Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX

April 8
Last Trade: 0.82 -0.03 -2.98

TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved...Read more


Medtronic: SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women

April 7
Last Trade: 79.48 0.29 0.37

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and ATLANTA, April 7, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement...Read more


Medtronic: New survey uncovers lack of awareness around heart valve disease and risk factors among women

April 7
Last Trade: 79.48 0.29 0.37

Despite prevalence of chronic conditions associated with aortic stenosis in women over 65, the majority have never been referred to a cardiologist; Racial disparities may present further opportunities for awareness amongst women at risk for cardiovascular disease   DUBLIN, April 7, 2024 /CNW/ -- Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women's...Read more


Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

April 5
Last Trade: 201.48 2.03 1.02

Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C., April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular...Read more


Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

April 5
Last Trade: 85.28 -2.00 -2.29

Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months AUSTIN, Texas / Apr 05, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Today's Medical Gainers

 
CompanyChangeLast Trade
Atrion 16.65 4.32 $402.35
McKesson 6.02 1.16 $524.83
Thermo Fisher Scientific 3.26 0.60 $544.78
Quest Diagnostics 2.53 2.01 $128.44
Cardinal Health 2.19 2.07 $108.19
Abbott 2.03 1.93 $107.30
Labcorp 2.03 1.02 $201.48
Waters 1.87 0.64 $296.10
CONMED 1.56 2.19 $72.64
Insulet 1.52 0.92 $166.25
ShockWave Medical 1.48 0.45 $329.00
Lantheus 1.48 2.37 $63.81
Revvity 1.48 1.49 $100.86
Glaukos 1.37 1.44 $96.50
Utah Medical Products 1.35 2.01 $68.58
Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE
List of Medical Stocks

Medical Stocks

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB